Switching from originator adalimumab to a biosimilar did not impact clinical outcomes or lead to worse patient-reported perceptions of effectiveness.
Industry news
Switching from originator adalimumab to a biosimilar did not impact clinical outcomes or lead to worse patient-reported perceptions of effectiveness.
recently published
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.